• Explore /
  • Poster
  • / Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.

Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.

Abstract Poster

Authors

null

Takefumi Komiya

Hematology/Medical Oncology, Parkview Cancer Institute, Fort Wayne, IN

Takefumi Komiya , Jun Zhang , Prakash C. Neupane , Kathan Mehta , Chao Hui Huang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT04467723

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2678)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2678

Abstract #

TPS2678

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Heather A. Wakelee

First Author: Steven H. Lin

First Author: Vassiliki Papadimitrakopoulou

First Author: Antoine Italiano